Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.
Krop IE, Mayer IA, Ganju V, Dickler M, Johnston S, Morales S, Yardley DA, Melichar B, Forero-Torres A, Lee SC, de Boer R, Petrakova K, Vallentin S, Perez EA, Piccart M, Ellis M, Winer E, Gendreau S, Derynck M, Lackner M, Levy G, Qiu J, He J, Schmid P. Krop IE, et al. Among authors: vallentin s. Lancet Oncol. 2016 Jun;17(6):811-821. doi: 10.1016/S1470-2045(16)00106-6. Epub 2016 May 4. Lancet Oncol. 2016. PMID: 27155741 Free PMC article. Clinical Trial.
Low CYP1A2 activity associated with testicular cancer.
Vistisen K, Loft S, Olsen JH, Vallentin S, Ottesen S, Hirsch FR, Poulsen HE. Vistisen K, et al. Among authors: vallentin s. Carcinogenesis. 2004 Jun;25(6):923-9. doi: 10.1093/carcin/bgh102. Epub 2004 Feb 19. Carcinogenesis. 2004. PMID: 14976127
Delineation of target volumes and organs at risk in adjuvant radiotherapy of early breast cancer: national guidelines and contouring atlas by the Danish Breast Cancer Cooperative Group.
Nielsen MH, Berg M, Pedersen AN, Andersen K, Glavicic V, Jakobsen EH, Jensen I, Josipovic M, Lorenzen EL, Nielsen HM, Stenbygaard L, Thomsen MS, Vallentin S, Zimmermann S, Offersen BV; Danish Breast Cancer Cooperative Group Radiotherapy Committee. Nielsen MH, et al. Among authors: vallentin s. Acta Oncol. 2013 May;52(4):703-10. doi: 10.3109/0284186X.2013.765064. Epub 2013 Feb 19. Acta Oncol. 2013. PMID: 23421926
Attitudes and perceptions towards epilepsy in an onchocerciasis-endemic region of Tanzania: a mixed approach to determine the magnitude and driving factors.
Mushi VP, Kidima W, Massawe IS, Magili PF, Bhwana D, Kaaya RE, Kimambo H, Hyera HF, Matuja W, Sen A, Sander JW, Colebunders R, Mahone S, Newton CR, Mmbando BP; EPInA Study Group. Mushi VP, et al. BMC Public Health. 2024 Sep 27;24(1):2608. doi: 10.1186/s12889-024-20108-5. BMC Public Health. 2024. PMID: 39333993 Free PMC article.
Prevalence of all epilepsies in urban informal settlements in Nairobi, Kenya: a two-stage population-based study.
Mwanga DM, Kadengye DT, Otieno PO, Wekesah FM, Kipchirchir IC, Muhua GO, Kinuthia JW, Kwasa T, Machuka A, Mongare Q, Iddi S, Davis Jones G, Sander JW, Kariuki SM, Sen A, Newton CR, Asiki G; EPInA Study Group. Mwanga DM, et al. Lancet Glob Health. 2024 Aug;12(8):e1323-e1330. doi: 10.1016/S2214-109X(24)00217-1. Epub 2024 Jul 5. Lancet Glob Health. 2024. PMID: 38976998 Free PMC article.
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A; ExteNET Study Group. Martin M, et al. Lancet Oncol. 2017 Dec;18(12):1688-1700. doi: 10.1016/S1470-2045(17)30717-9. Epub 2017 Nov 13. Lancet Oncol. 2017. PMID: 29146401 Clinical Trial.